Study launched exploring novel BET inhibitor plus pembrolizumab and enzalutamide in mCRPC
March 17th 2021The study is evaluating the triplet in patients with metastatic castration-resistant prostate cancer who have become resistant to first-line treatment with an androgen receptor signaling inhibitor.